(Total Views: 339)
Posted On: 09/19/2025 2:52:18 PM
Post# of 157143
Speaking of legacies and agreements.
Oct 17th, 2012, Progenics was paid $3.5Million upfront for transferring ownership to Cytodyn for Pro140.
Upon commencement of Phase3 it calls for a $1.5 Million in milestone payments...
In the event of the First new drug application Approval another $5 million.
An additional Royalty payment of 5% on Net sales upon commercialization.
Oct 17th, 2012, Progenics was paid $3.5Million upfront for transferring ownership to Cytodyn for Pro140.
Upon commencement of Phase3 it calls for a $1.5 Million in milestone payments...
In the event of the First new drug application Approval another $5 million.
An additional Royalty payment of 5% on Net sales upon commercialization.
(6)
(0)
